ERS Genomics:
The global CRISPR/Cas9 licensing leader

Based on the Nobel Prize winning invention of Emmanuelle Charpentier and Jennifer Doudna, CRISPR/Cas9 has transformed gene editing. ERS licenses worldwide access to the essential CRISPR/Cas9 patent portfolio.

CRISPR has been used to identify factors essential for #SARSCoV2 infection in humans. A genome-wide #CRISPR screen uncovered potential targets which may be exploited to develop drugs again SARS-CoV-2 infection. Read more @NatureGenet: https://t.co/Bh922vmUW4

ERS Genomics

We are excited to announce ERS Genomics' new website, showcasing our expertise in CRISPR #IP and as a global leader in #CRISPRCas9 licensing, is now live. To learn more visit: https://t.co/AvqKyYCUnj

ERS Genomics

#CRISPR has been used to create brain-like 'organoids' using human #stemcells. The organoids, containing an ancient version of NOVA1, the gene influencing brain development, were smaller and bumpier than those with human #genes. Read more @nresearchnews: https://t.co/PzwiFy9YJe

Dr. Emmanuelle Charpentier

ERS co-founder, patent co-owner, and 2020 Nobel Prize winner

The essential intellectual property for the practice of CRISPR/Cas9

Consisting of over 50 granted patents in over 80 countries, our portfolio represents the most foundational collection of CRISPR/Cas9 patents worldwide.

Empowering the CRISPR/Cas9
platform globally

Non-exclusive licenses are available to companies for internal research and sale of products and services, in a wide range of fields.

ERS Genomics:
The global CRISPR/Cas9 licensing leader

Based on the Nobel Prize winning invention of Emmanuelle Charpentier and Jennifer Doudna, CRISPR/Cas9 has transformed gene editing. ERS licenses worldwide access to the essential CRISPR/Cas9 patent portfolio.

Dr. Emmanuelle Charpentier

ERS co-founder, patent co-owner, and 2020 Nobel Prize winner

The essential intellectual property for the practice of CRISPR/Cas9

Empowering the CRISPR/Cas9
platform globally

Pharmaceutical & biotech

Agriculture & livestock

Industrial & synthetic biology

CRO, CMO & tools providers

Companion animal/ veterinary medicine

Recent news

ERS Genomics and Setsuro Tech sign CRISPR/Cas9 license agreement

ERS Genomics licenses CRISPR gene editing technology to Otsuka Pharmaceutical

ERS Genomics expands team with appointment of Jon Kratochvil as VP Business Development

Contact us to discuss a license

The global CRISPR/Cas9 licensing leader

ERS Genomics: The global CRISPR/Cas9 licensing leader

Based on the Nobel Prize winning invention of Emmanuelle Charpentier and Jennifer Doudna, CRISPR/Cas9 has transformed gene editing. ERS licenses worldwide access to the essential CRISPR/Cas9 patent portfolio.

Dr. Emmanuelle Charpentier

ERS co-founder, patent co-owner, and 2020 Nobel Prize winner

The essential intellectual property for the practice of CRISPR/Cas9

Empowering the CRISPR/Cas9 platform globally

Pharmaceutical & biotech

Agriculture & livestock

Industrial & synthetic biology

CRO, CMO & tools providers

Companion animal/ veterinary medicine

Recent news

ERS Genomics and Setsuro Tech sign CRISPR/Cas9 license agreement

ERS Genomics licenses CRISPR gene editing technology to Otsuka Pharmaceutical

ERS Genomics expands team with appointment of Jon Kratochvil as VP Business Development

Contact us to discuss a license

The global CRISPR/Cas9 licensing leader

ERS Genomics:
The global CRISPR/Cas9 licensing leader

Empowering the CRISPR/Cas9
platform globally